Posts Tagged ‘c8-optical-glucose-monitoring’

C8 Non-Invasive Optical Glucose Monitor System Cleared for Sale in Europe

C8 Non-Invasive Optical Glucose Monitor System Cleared for Sale in Europe

C8 Non-Invasive Optical Glucose Monitor System Cleared for Sale in Europe

A new non-invasive continuous glucose monitor is approved for marketing in Europe

C8 MediSensors, Inc. (http://www.c8medisensors.com) has today announced it received CE Mark approval for its Optical Glucose Monitor System, allowing the device, a new non-invasive continuous glucose monitor (nCGM), to be marketed in Europe.

(Logo: http://photos.prnewswire.com/prnh/20121024/567690 )

The comprehensive, 10-year Diabetes Control and Complications Trial (DCCT) clearly demonstrated that individuals with type 1 diabetes who kept blood glucose levels as close to normal as possible for as long as possible had less chance of developing disease-related complications. The DCCT found that the risk of eye disease was reduced by 76%, kidney disease by 50% and nerve disease by 60%.[1]Since that time, other studies have confirmed the importance of tight glycaemic control with minimal glucose excursions in reducing disease-related complications not only in type 1 diabetes, but also in type 2.[2-6] In addition, a large number of studies have shown that continuous glucose monitors (CGM) can improve glycaemic control with reduced risk of hypoglycaemia.[7-19]

CGMs are adjunct devices that are intended to complement finger stick blood glucose tests. Traditional CGMs rely on a needle sensor inserted under the skin, which can cause pain or discomfort, and pose a risk of infection.[20] In contrast, the C8 MediSensors Optical Glucose Monitor System harnesses the power of light to measure glucose levels. Using Raman spectroscopy, a beam of light is shone into the skin and the resulting vibrations of glucose molecules are measured to give a glucose reading; all achieved via a small, pain-free portable monitor, discreetly worn under clothes against the skin.

For added convenience these readings are stored and sent wirelessly to the user’s smartphone for glucose readings at a glance, providing the wearer with a continuous picture of glucose dynamics throughout the day. A good understanding of glucose levels is invaluable in managing diabetes and improving patient outcomes.[1]In clinical studies, the C8 MediSensors monitor was found to have accuracy comparable to earlier versions of invasive CGMs when those systems were first introduced, but with less pain and less risk of infection.

“C8 MediSensors was co-founded by a father trying to help his son living with diabetes, and as a company, we remain dedicated to helping those with the disease,” said Paul Zygielbaum, CEO of C8 MediSensors. “CE Mark approval is a landmark step for this unique technology. Our team is hugely excited to be working to make nCGM and the Optical Glucose Monitor System available throughout Europe.”

The C8 MediSensors Optical Glucose Monitor System will initially be available for purchase online via the C8 MediSensors website, http://www.c8medisensors.com.

The C8 MediSensors Optical Glucose Monitor System is an adjunct device. It is contraindicated in pregnancy and for those under 18 years of age, as well as in individuals with very light or very dark skin tones, peripheral vascular disease or individuals who smoke.

-ends-

Notes to editors:

About C8 MediSensors

C8 MediSensors is the leader in non-invasive continuous glucose monitoring. Headquartered in San Jose CA, C8 MediSensors’ breakthrough patent-protected technology gives people with diabetes a continuous view of their glucose levels, without the pain, inconvenience and high cost of invasive continuous glucose monitoring. Visit http://www.c8medisensors.com.

Additional background information on ‘Diabetes and continuous glucose monitoring’ and ‘C8 MediSensors and the Optical Glucose Monitor’ are available from the European media contacts below.

This document contains forward-looking statements. Any statements contained in this document that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the company’s anticipated product sales and financing needs. These forward-looking statements are based upon the company’s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for the product, and risks and uncertainties associated with the company’s business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

People with diabetes long for a glucose monitor that is accurate, continuous, non-invasive, and non-intrusive. Our goals focus on improving health, quality of life, and reducing risks of long-term diabetes-related complications by minimizing glucose variability.

Our optical technology provides continuous glucose monitoring that we believe can help people with diabetes achieve better glycemic control without the complexity, inconvenience, and pain of current invasive methods.

C8 MediSensors, a San Jose, California company, maybe making a bit of history by receiving the European CE Mark for their Optical Glucose Monitor System. The firm’s sensor uses Raman spectroscopy to non-invasively detect glucose in blood by shining light through the skin and detecting changes in the returning spectrum.

Once the sensor is attached to the skin it sends out regular readings wirelessly over Bluetooth to a smartphone, allowing for tight glycemic control and near instant alerts when glucose levels go outside preset parameters. It’s currently compatible with Android phones and an iOS app is expected to be available next year.

From the product page:

The C8 MediSensors monitor does not require constant recalibration to maintain sensor accuracy. Except for periodic baseline reference measurements, there is no need for ongoing finger sticks to constantly recalibrate the C8 MediSensors monitor. After being removed and put back on, the monitor will resume measuring glucose – no recalibration or sensor replacement required.

Our technique involves shining a monochromatic light source into the skin and detecting the scattered light. The colors generated by Raman scattering are very specific to the exact chemical structure of the molecules in the sample. The molecules’ various shapes, sizes, atoms, and types of chemical bonds will generate unique Raman spectra, a unique Raman “fingerprint” that can be used to non-invasively read and measure glucose.

Source : http://www.prnewswire.com/news-releases/c8-medisensors-gains-ce-mark-approval-for-the-c8-medisensors-optical-glucose-monitortm-system-for-people-with-diabetes-175821951.html

Related Posts Plugin for WordPress, Blogger...

Full story

Copyright © 2018 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes